Quotient Addresses Subject Biomarker Prescreening for Enrollment


Company News Release

Quotient Bioresearch (Quotient), a provider of early stage and specialist drug development services, has announced an expansion to its molecular biology service offering.

With the increasing demand for pharmacogenomic stratification of subjects prior to clinical trial enrolment, Quotient has established Real-Time PCR to support screening of subjects. Building on their existing Real-Time PCR instrumentation, Quotient has invested in the latest 384-well format, instrument from Life Technologies, the ViiA7™, to support this strategic move.

This service arose from the microbiology group at Quotient (formerly GR Micro), with more than 13 years’ experience in molecular characterization, to support the development of anti-infectives. The integration of microbiology within Quotient’s bioanalytical, biomarker and central lab services in 2007 and subsequent investment has broadened the molecular offering available to customers.  Synergy with the chemistry, metabolism and clinical services offered by Quotient further enhances the scientific expertise available to help customers through the regulatory process and bring products to market.

Supported by the latest mass spectrometry and immunochemistry technologies, a full range of microbiology services, central lab services and now high-throughput Real-Time PCR instrumentation, Quotient’s team offers in-depth expertise spanning small molecules, biopharmaceuticals, antimicrobials and molecular biology.

For further information about Quotient’s molecular biology services visit the website.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.